Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 6.9% Higher

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s share price rose 6.9% during trading on Thursday . The stock traded as high as $16.88 and last traded at $16.88. Approximately 279,251 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 588,427 shares. The stock had previously closed at $15.79.

Analysts Set New Price Targets

DAWN has been the topic of several recent research reports. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Piper Sandler restated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.60.

Day One Biopharmaceuticals Trading Up 4.6 %

The stock’s 50-day moving average is $15.11 and its 200-day moving average is $13.52.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Analysts expect that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now directly owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The disclosure for this sale can be found here. Insiders sold a total of 45,781 shares of company stock worth $722,960 in the last 90 days. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. RA Capital Management L.P. lifted its holdings in shares of Day One Biopharmaceuticals by 10.9% in the second quarter. RA Capital Management L.P. now owns 7,809,852 shares of the company’s stock valued at $93,250,000 after purchasing an additional 769,230 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Day One Biopharmaceuticals by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 4,769,746 shares of the company’s stock worth $69,638,000 after purchasing an additional 139,992 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Day One Biopharmaceuticals by 4.2% during the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock valued at $61,857,000 after acquiring an additional 169,463 shares during the last quarter. Braidwell LP raised its position in shares of Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after purchasing an additional 500,000 shares during the period. Finally, BlackRock Inc. raised its holdings in Day One Biopharmaceuticals by 57.8% in the 2nd quarter. BlackRock Inc. now owns 3,564,733 shares of the company’s stock worth $42,563,000 after acquiring an additional 1,306,238 shares during the period. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.